Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical ...

Trace Neuroscience, Inc., a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases, today announced the initiation of its global clinical ...

Neuroscience is a vast field of study containing a range of narrower subfields. Each involves a spotlight on the brain and other parts of the nervous system, connecting them to one or more zones of ...

– Convergent clinical and preclinical evidence supports the mechanistic link between ALTO-300 and the biomarker, a measure of greater EEG irregularity, being used for patient selection – – Completed ...

The 1990s were declared the "Decade of the Brain"—yet, 25 years later, much about the brain remains a mystery. Our brain is the most protected and least accessible organ in the human body, making real ...

JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central ...

First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter ...

Oral prolonged-release ketamine formulation (KET01) demonstrates minimal dissociation and cardiovascular effects with early antidepressant efficacy signals in treatment-resistant depressionResults ...

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective ...

Amygdala Neurosciences Inc. has selected ANS-858 as its lead clinical candidate for substance use disorders, that includes alcohol and cocaine use disorders. The selective, reversible, orally ...

Addiction remains one of the most pressing public health challenges of our time, and the landscape is shifting fast. The rise of synthetic opioids and ...